Form 8-K Intellia Therapeutics, For: Apr 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'
April 27, 2026 10:48 AM EDTTD Cowen analyst Joseph Thome reiterated a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA released Ph. III data of its in vivo gene editing candidate lonvo-z for the treatment of HAE this morning. The trial hit both primary and... More
